Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

3.855 +0.035 (+0.92%)

Streaming Delayed Price Updated: 1:29 PM EDT, May 26, 2026 Add to My Watchlist

Price and Volume

Volume	498,405
Open	3.830
Bid (Size)	3.850 (1,300)
Ask (Size)	3.860 (1,300)
Prev. Close	3.820
Today's Range	3.720 - 3.880
52wk Range	3.530 - 8.590
Shares Outstanding	93,500,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

1 Unprofitable Stock to Consider Right Now and 2 We Turn Down

May 22, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

May 15, 2026

The Netflix star partners with Myriad Genetics to tell her BRCA1 story and why she wants everyone to know about hereditary cancer testing

From Myriad Genetics, Inc.

Via GlobeNewswire

Performance

YTD	-37.2%	-37.2%
1 Month	-20.2%	-20.2%
3 Month	-12.0%	-12.0%
6 Month	-50.1%	-50.1%
1 Year	-7.1%	-7.1%

More News

Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

May 12, 2026

Via StockStory

Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS ↗

May 05, 2026

Via Chartmill

3 of Wall Street’s Favorite Stocks with Open Questions

May 12, 2026

Via StockStory

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

May 07, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins

May 06, 2026

Via StockStory

Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%

May 05, 2026

Via StockStory

Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business

May 05, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect

May 03, 2026

Via StockStory

Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan

April 30, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026

April 28, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

3 Small-Cap Stocks We Think Twice About

April 24, 2026

Via StockStory

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

April 16, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

April 14, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

1 Cash-Burning Stock to Target This Week and 2 We Question

April 13, 2026

Via StockStory

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

April 09, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

April 05, 2026

Via StockStory

3 Healthcare Stocks with Open Questions

April 02, 2026

Via StockStory

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know

March 27, 2026

Via StockStory

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

March 17, 2026

From Myriad Genetics, Inc.

Via GlobeNewswire

2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off

March 17, 2026

Via StockStory

Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc

March 11, 2026

Via StockStory

3 Reasons to Sell MYGN and 1 Stock to Buy Instead

March 11, 2026

Via StockStory

Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know

March 10, 2026

Via StockStory

Frequently Asked Questions

Is Myriad Genetics, Inc. - Common Stock publicly traded?

Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.

What exchange does Myriad Genetics, Inc. - Common Stock trade on?

Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?

The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market

What is the current price of Myriad Genetics, Inc. - Common Stock?

The current price of Myriad Genetics, Inc. - Common Stock is 3.855

When was Myriad Genetics, Inc. - Common Stock last traded?

The last trade of Myriad Genetics, Inc. - Common Stock was at 05/26/26 01:29 PM ET

What is the market capitalization of Myriad Genetics, Inc. - Common Stock?

The market capitalization of Myriad Genetics, Inc. - Common Stock is 360.44M

How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?

Myriad Genetics, Inc. - Common Stock has 360M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.